Royal Bank Of Canada Increases Haleon (LON:HLN) Price Target to GBX 390

Haleon (LON:HLN) had its price objective increased by analysts at Royal Bank Of Canada from GBX 370 to GBX 390 in a report issued on Tuesday,Digital Look reports. The brokerage presently has a “sector perform” rating on the stock. Royal Bank Of Canada’s target price indicates a potential upside of 6.89% from the company’s previous close.

HLN has been the subject of a number of other research reports. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 400 target price on shares of Haleon in a report on Friday, July 31st. Berenberg Bank increased their price target on shares of Haleon from GBX 512 to GBX 514 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Haleon from GBX 325 to GBX 335 and gave the company a “sell” rating in a research report on Friday, July 31st. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Haleon from GBX 335 to GBX 315 and set an “underweight” rating for the company in a research note on Thursday, June 25th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Haleon presently has a consensus rating of “Hold” and an average target price of GBX 399.

Haleon Price Performance

Haleon stock opened at GBX 364.86 on Tuesday. The firm has a market capitalization of £32.14 billion, a P/E ratio of 20.16, a PEG ratio of 1.49 and a beta of 0.24. Haleon has a one year low of GBX 317.80 and a one year high of GBX 416.10. The company has a debt-to-equity ratio of 52.26, a current ratio of 0.92 and a quick ratio of 0.93. The business has a fifty day moving average price of GBX 352.91 and a 200-day moving average price of GBX 363.12.

Haleon (LON:HLN) last released its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 earnings per share (EPS) for the quarter. Haleon had a return on equity of 10.30% and a net margin of 15.11%. As a group, equities research analysts forecast that Haleon will post 19.5033282 EPS for the current year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.